#1 Clinical Trials Search in Europe

Magnesium Citrate

Clinical trials investigating “Magnesium Citrate” are not shown in the provided trial data. The trials listed here study remibrutinib compared with teriflunomide in people with relapsing multiple sclerosis, and they look at relapse frequency and safety. Both studies are Phase 3, interventional trials with large participant groups.

Table of Contents

Trial overview

The provided data does not show any clinical trials of Magnesium Citrate. Instead, it shows two clinical trials studying remibrutinib compared with teriflunomide in people with relapsing multiple sclerosis.[1][2]

Both trials are listed as authorised and are designed as interventional studies, which means the researchers are giving treatments and comparing results between groups.[1][2]

Study design and phase

Both studies are Phase 3 trials, which is a later stage of testing in a larger group of people.[1][2]

Phase 3 trials are usually used to see how well a treatment works and to continue checking safety in a bigger population.[1][2]

The two trials are very similar in design, and both plan long-term treatment with remibrutinib after the comparison period.[1][2]

Who the trials are for

The target population in both studies is people with relapsing multiple sclerosis, a type of multiple sclerosis where symptoms come back in attacks called relapses.[1][2]

The source data does not give extra details about age limits, sex, or other entry rules for participation.[1][2]

What is being measured

The main endpoint in both trials is the annualized relapse rate (ARR) of confirmed relapses.[1][2]

ARR means the average number of relapses per year, and confirmed relapses are relapses that meet the study rules for counting them.[1][2]

The brief summary in both trials says the goal is to show that remibrutinib is better than teriflunomide at reducing the number of confirmed relapses.[1][2]

Details of the two trials

NCT05147220 is a Phase 3 interventional trial in relapsing multiple sclerosis with planned enrollment of 1009 participants.[1]

This study compares remibrutinib with teriflunomide and includes long-term treatment with remibrutinib after the main comparison.[1]

NCT05156281 is another Phase 3 interventional trial in relapsing multiple sclerosis with planned enrollment of 1058 participants.[2]

This study has the same overall goal: to show that remibrutinib reduces confirmed relapses more than teriflunomide, followed by long-term remibrutinib treatment.[2]

Both studies are large, which helps researchers collect enough data to compare the treatments in a reliable way.[1][2]

Key terms explained

  • Multiple sclerosis: a disease that affects the brain and spinal cord and can cause different symptoms over time.
  • Relapse: a period when symptoms get worse again after being better for a while.
  • Confirmed relapse: a relapse that has been checked and counted by the study team.
  • Interventional study: a study where people receive a treatment so researchers can compare results.
  • Placebo: an inactive treatment used for comparison in some studies.
  • Primary outcome: the main result the researchers want to measure.
  • Enrollment: the number of participants planned for the trial.
Trial ID Phase Condition studied Status Enrollment Main endpoint
NCT05147220 Phase 3 Multiple Sclerosis Authorised 1009 Annualized relapse rate (ARR) of confirmed relapses
NCT05156281 Phase 3 Multiple Sclerosis Authorised 1058 Annualized relapse rate (ARR) of confirmed relapses

FAQ

  • What clinical trials are listed in the provided data? The provided data lists two Phase 3 interventional trials in relapsing multiple sclerosis. Both compare remibrutinib with teriflunomide and then continue long-term treatment with remibrutinib.
  • Who can take part in these trials? The trials are for participants with relapsing multiple sclerosis. The data does not give more details about age, sex, or other entry rules.
  • What is being measured in these trials? The main measure is the annualized relapse rate, or ARR. This means how often confirmed relapses happen over time.
  • What phase are these trials? Both trials are Phase 3. Phase 3 studies usually test how well a treatment works in a larger group of people and continue to look at safety.
  • Is Magnesium Citrate being studied in these trials? No. The provided trial data does not include any study of Magnesium Citrate. It only includes trials of remibrutinib and teriflunomide in multiple sclerosis.

Ongoing Clinical Trials on Magnesium Citrate

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Estonia France Germany +9

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Denmark Ireland +7

Glossary

  • Relapsing multiple sclerosis: A form of multiple sclerosis where symptoms get worse during relapses, then may improve for a time.
  • Interventional trial: A study where researchers give a treatment and compare outcomes between groups.
  • Phase 3: A later stage of clinical testing in a larger group of people to see how well a treatment works and to keep checking safety.
  • Annualized relapse rate (ARR): The average number of relapses a person has in one year.
  • Confirmed relapse: A relapse that has been checked and counted using the study rules.
  • Placebo: An inactive treatment used to compare with a real drug in a study.
  • Teriflunomide: A drug used as a comparison treatment in these trials.
  • Remibrutinib: The study drug being compared with teriflunomide in both trials.
  • Long-term treatment: Treatment given for a longer time after the main part of the study.
  • Enrollment: The number of participants planned for a study.

References